OPKO Health, Inc. OCI, before Reclassifications, Net of Tax, Attributable to Parent
OPKO Health, Inc. (OPK) reported OCI, before Reclassifications, Net of Tax, Attributable to Parent of $17.84 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-18.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent · last filed 2021-02-18
- OPKO Health, Inc. oci, before reclassifications, net of tax, attributable to parent for fiscal 2020 was $17.84M.
- OPKO Health, Inc. oci, before reclassifications, net of tax, attributable to parent for fiscal 2019 was -$1.94M.
- OPKO Health, Inc. oci, before reclassifications, net of tax, attributable to parent for fiscal 2018 was -$14.73M, a 155.61% decline from fiscal 2017.
- OPKO Health, Inc. oci, before reclassifications, net of tax, attributable to parent for fiscal 2017 was $26.48M.
| Period end | OCI, before Reclassifications, Net of Tax, Attributable to Parent 12 month |
|---|---|
| 2020-12-31 | $17.84M 10-K · filed 2021-02-18 |
| 2019-12-31 | -$1.94M 10-K · filed 2021-02-18 |
| 2018-12-31 | -$14.73M 10-K · filed 2021-02-18 |
| 2017-12-31 | $26.48M 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |